The efficacy of the Soberana 02 vaccine candidate in its three-dose schedule together with Soberana Plus is 91.2%, which exceeds the World Health Organization (WHO) requirements for a vaccine candidate against COVID-19 to become a vaccine, which is 50%.
Design, obtaining and preclinical assessment of Cuban anti-Covid Soberana 02 vaccine candidate reached the headlines of the US magazine ACS Chemical Biology, paving the way for other antiviral vaccines.
The Immunoassay Center has developed a new product to diagnose the Sars-Cov-2 virus.
Cuban Public Health Minister Jose Angel Portal Miranda informed that the country is now under the community transmission phase for COVID-19 given the high contagious impact by the virus and the increase of its incidence levels over the past 15 days, add to this the circulation of highly contagious variants of the SARS-CoV-2.
The study of the Cuban anti-COVID candidate vaccine will include 350 children and adolescents, 50 in Phase I and 300 in Phase II, conducted in an overlapping and gradual process, in strict compliance with protocols and best practices.